# Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

> **NCT00472056** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 93 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Carmustine
- **DRUG:** Etoposide
- **DRUG:** Cytarabine
- **DRUG:** Melphalan
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00472056
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2016-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00472056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00472056, "Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00472056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*